Basilea Pharmaceutica Ltd (BSLN.XSWX) DCF Valuation
Every assumption below is yours to change. The defaults are derived from this company's own filing history, not from a house view.
Conservative
CHF 113.97
74% undervaluedvs CHF 65.60
Base
CHF 189.85
189% undervaluedvs CHF 65.60
Optimistic
CHF 355.63
442% undervaluedvs CHF 65.60
Where today's price sits
Today's price falls outside the modelled range.
Verdict
Today's price sits below all three scenarios. Under these assumptions the stock looks undervalued, which is only as reliable as the growth rates you have entered.
Base free cash flow
CHF 59M
Trailing twelve months
Historical FCF CAGR
+99.3%
Across 6 reported periods
Market implies
-3.8%
Growth needed at 8% WACC
Terminal value share
69%
Of the base case valuation
Growth needed to justify today's price
At a 8.0% discount rate, today's price already assumes -3.8% annual free cash flow growth for ten years. Your base case assumes 20.0%, so you are forecasting more growth than the price requires.
Curve holds terminal growth at 2.5%, years 6 to 10 at half the first-stage rate, and applies no safety margin.
Free cash flow history
The most recent period is the base every projection starts from. Compounded, that history is +99.3% a year.
Basilea Pharmaceutica (BSLN.XSWX) DCF: intrinsic value and margin of safety
Intrinsiqq's two-stage DCF values Basilea Pharmaceutica (BSLN.XSWX) at about CHF 253.13 per share, or CHF 189.85 with a 25% margin of safety. At CHF 65.60 the stock looks undervalued. Every assumption is adjustable below; this is analysis, not investment advice.
Frequently asked
What is Basilea Pharmaceutica's (BSLN.XSWX) fair value?+
Intrinsiqq's two-stage discounted cash flow (DCF) model estimates an intrinsic value of about CHF 253.13 per share for BSLN.XSWX. It projects recent free cash flow forward at a growth rate that fades toward a long-run rate, then discounts those cash flows back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around CHF 189.85. The output moves with the growth and discount-rate inputs, so it is best read as a range, not a single number. You can change every assumption with the sliders on this tab.
Is Basilea Pharmaceutica overvalued based on a DCF?+
At CHF 65.60, BSLN.XSWX trades below the base-case intrinsic value of about CHF 253.13, a 285.9% discount to that estimate, so on this model it looks undervalued. A DCF is only one lens: a premium can be justified if the business grows faster or is higher quality than the base case assumes, which is exactly what the sliders let you test.
What growth is priced into Basilea Pharmaceutica?+
The base case grows BSLN.XSWX's free cash flow at about 20.0% a year before fading, against roughly 99.3% historical free-cash-flow growth. If the price implies growth well above what the company has actually delivered, the market is paying for optimism; if below, expectations are modest. Adjust the growth assumption on this tab to see what the current price is really betting on.
What is a good margin of safety for Basilea Pharmaceutica?+
A margin of safety is the discount to intrinsic value you demand before buying, to protect against being wrong on the inputs. Intrinsiqq applies 25% by default, which turns BSLN.XSWX's CHF 253.13 intrinsic estimate into a CHF 189.85 entry. Wider margins suit less predictable businesses; you can set your own on this tab. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.